Literature DB >> 12445555

Potential roles of antisense oligonucleotides in cancer therapy. The example of Bcl-2 antisense oligonucleotides.

Nathalie Dias1, C A Stein.   

Abstract

Antisense oligonucleotides have been widely used to specifically and selectively downregulate gene expression at the messenger RNA level. Even though oligonucleotides are commonly used in laboratories and clinical trials, they can induce non-specific effects that can lead to misinterpretation of experimentally-derived results. This review summarizes precautions one should take when using oligonucleotides. In addition, the role of one oligonucleotide, G3139, which is targeted to the coding region of bcl-2 messenger RNA, in inhibiting tumor progression in vitro and in clinical trials, is described.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12445555     DOI： 10.1016/s0939-6411(02)00060-7

Source DB:  PubMed          Journal:  Eur J Pharm Biopharm        ISSN： 0939-6411            Impact factor:   5.571


  18 in total

1.  Respiratory syncytial virus infection sensitizes cells to apoptosis mediated by tumor necrosis factor-related apoptosis-inducing ligand.

Authors:  Alexander Kotelkin; Elena A Prikhod'ko; Jeffrey I Cohen; Peter L Collins; Alexander Bukreyev
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

2.  The BCL-2 5' untranslated region contains an RNA G-quadruplex-forming motif that modulates protein expression.

Authors:  Ramla Shahid; Anthony Bugaut; Shankar Balasubramanian
Journal:  Biochemistry       Date:  2010-09-28       Impact factor: 3.162

Review 3.  Chemotherapeutic approaches for targeting cell death pathways.

Authors:  M Stacey Ricci; Wei-Xing Zong
Journal:  Oncologist       Date:  2006-04

4.  From Influenza Virus Infections to Lupus: Synchronous Estrogen Receptor α and RNA Polymerase II Binding Within the Immunoglobulin Heavy Chain Locus.

Authors:  Bart G Jones; Robert E Sealy; Rhiannon R Penkert; Sherri L Surman; Barbara K Birshtein; Beisi Xu; Geoffrey Neale; Robert W Maul; Patricia J Gearhart; Julia L Hurwitz
Journal:  Viral Immunol       Date:  2020-02-27       Impact factor: 2.257

Review 5.  Canonical and non-canonical barriers facing antimiR cancer therapeutics.

Authors:  Christopher J Cheng; W Mark Saltzman; Frank J Slack
Journal:  Curr Med Chem       Date:  2013       Impact factor: 4.530

Review 6.  Nanogels: An overview of properties, biomedical applications and obstacles to clinical translation.

Authors:  Kruti S Soni; Swapnil S Desale; Tatiana K Bronich
Journal:  J Control Release       Date:  2015-11-10       Impact factor: 9.776

7.  Delivery of antisense oligodeoxyribonucleotide lipopolyplex nanoparticles assembled by microfluidic hydrodynamic focusing.

Authors:  Chee Guan Koh; Xulang Zhang; Shujun Liu; Sharon Golan; Bo Yu; Xiaojuan Yang; Jingjiao Guan; Yan Jin; Yeshayahu Talmon; Natarajan Muthusamy; Kenneth K Chan; John C Byrd; Robert J Lee; Guido Marcucci; L James Lee
Journal:  J Control Release       Date:  2009-08-28       Impact factor: 9.776

8.  Nanogels for oligonucleotide delivery to the brain.

Authors:  Serguei V Vinogradov; Elena V Batrakova; Alexander V Kabanov
Journal:  Bioconjug Chem       Date:  2004 Jan-Feb       Impact factor: 4.774

9.  A novel concept for ligand attachment to oligonucleotides via a 2'-succinyl linker.

Authors:  Johannes Winkler; Ernst Urban; Doris Losert; Volker Wacheck; Hubert Pehamberger; Christian R Noe
Journal:  Nucleic Acids Res       Date:  2004-02-02       Impact factor: 16.971

10.  2'-O-methyl-modified phosphorothioate antisense oligonucleotides have reduced non-specific effects in vitro.

Authors:  Byong Hoon Yoo; Elena Bochkareva; Alexey Bochkarev; Tung-Chung Mou; Donald M Gray
Journal:  Nucleic Acids Res       Date:  2004-04-02       Impact factor: 16.971
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.